Medite Cancer Diagnostics, Inc.
OTC: MDIT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- Rahsan-Rahsan Lindsay
- Employees
- 69
- Headquarters
- Orlando, United States
- IPO year
- 1995
- Market cap
- $8.7K
- Website
- https://medite-group.com
Loading MDIT…
Loading profile data…Frequently asked questions about MDIT
What does Medite Cancer Diagnostics, Inc. (MDIT) do?
Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrumen...
Where does MDIT trade?
Medite Cancer Diagnostics, Inc. (MDIT) trades on the Other OTC.
What sector is MDIT in?
Medite Cancer Diagnostics, Inc. (MDIT) operates in the Healthcare sector, specifically in the Medical - Specialties industry.
Who is the CEO of Medite Cancer Diagnostics, Inc.?
Rahsan-Rahsan Lindsay is the chief executive officer of Medite Cancer Diagnostics, Inc. (MDIT).
Where is Medite Cancer Diagnostics, Inc. headquartered?
Medite Cancer Diagnostics, Inc. is headquartered in United States.
Does MDIT pay a dividend?
Medite Cancer Diagnostics, Inc. (MDIT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MDIT go public?
Medite Cancer Diagnostics, Inc. (MDIT) completed its initial public offering in 1995.